These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30764089)

  • 1. Preserving insulin secretion in Type 2 diabetes mellitus.
    Tibaldi J
    Expert Rev Endocrinol Metab; 2008 Mar; 3(2):147-159. PubMed ID: 30764089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes.
    Mudaliar S
    Int J Clin Pract; 2013 Sep; 67(9):876-87. PubMed ID: 23952467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.
    Kendall DM; Kim D; Maggs D
    Diabetes Technol Ther; 2006 Jun; 8(3):385-96. PubMed ID: 16800760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2012 Feb; 14(2):101-11. PubMed ID: 21752172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH
    Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus.
    Walter H; Lübben G
    Drugs; 2005; 65(1):1-13. PubMed ID: 15610048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass.
    Chon S; Gautier JF
    Diabetes Metab J; 2016 Apr; 40(2):99-114. PubMed ID: 27126881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?
    van Raalte DH; Verchere CB
    Diabetes Obes Metab; 2017 Sep; 19(9):1205-1213. PubMed ID: 28295962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical approaches to preserve beta-cell function in diabetes.
    Wajchenberg BL
    Adv Exp Med Biol; 2010; 654():515-35. PubMed ID: 20217513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 based therapy for type 2 diabetes.
    Arulmozhi DK; Portha B
    Eur J Pharm Sci; 2006 May; 28(1-2):96-108. PubMed ID: 16488579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin mimetics and enhancers for the treatment of type 2 diabetes mellitus.
    Ruige JB
    Acta Clin Belg; 2008; 63(2):81-5. PubMed ID: 18575047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin-based therapy and type 2 diabetes.
    Hare KJ; Knop FK
    Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients.
    Kheirandish M; Mahboobi H; Yazdanparast M; Kamal MA
    Curr Drug Metab; 2017; 18(2):157-162. PubMed ID: 28093996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.